The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News:
----------
Trafalgar Property Group PLC - south-east England-focused residential property developer - Reports no revenue for the first half of financial 2024 ended September 30, from £17,798 the year prior. Says pretax loss narrows to £214,270, from £444,137 previously. Chair Paul Treadway says: ‘The construction industry in general continues to be difficult and trying to find suitable development sites for the right price is becoming harder. The continued high inflation and high interest rates also impacts the general market conditions for property.’ In the year ended March 31, revenue fell to £18,183, form £64,839. Posts a pretax loss of £843,626, widening from £486,336.
----------
Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company - Says revenue falls to £4.2 million in the year ended September 30, from £18.7 million the year prior. Says pretax loss widens to £32.8 million, from £17.8 million previously. Chief Executive Lisa Anson says: ‘We are pleased to report significant progress across our pipeline of clinical and pre-clinical assets. Commencing our Phase 2a IPF clinical trial for our lead asset zelasudil, formerly RXC007, underscores our commitment to advancing our differentiated ROCK-inhibitor portfolio. During the year, we presented compelling preclinical data that demonstrate the potential of zelasudil in several other fibrotic indications that we intend to investigate further in the future.’
----------
Braveheart Investment Group PLC - Dodworth, England-based investment company - Says 100% held investee company Paraytec Ltd confirms its CX300 instrument can detect and discriminate gram-positive and gram-negative bacteria in human blood samples within 90 minutes. University of Sheffield Professor Carl Smythe says: ‘The Paraytec test has been shown to be highly effective in distinguishing between gram-positive and gram-negative bacteria. The test currently takes approximately 90 minutes to provide a test result from receiving a sample and does not require time-consuming blood culture. This is a significant achievement and a point-of-care instrument using this technology could provide diagnosing clinicians with a rapid indication of which antibiotic type to prescribe, as well as the likely location of infection and degree of virulence.’
----------
Allergy Therapeutics PLC - Sussex-based biotechnology company - Says it requires additional time to complete its audit for the year ended June 30., as a result of limited resource availability in its audit engagement team. Says it will miss its publishing deadline of December 31, meaning its shares will be suspended on January 2. Says its final audit is expected by the end of January.
----------
Directa Plus PLC - London-based graphene product maker - Says it has expanded its collaboration with CIA Miguel Caballero, a bulletproof vest and personal protective equipment manufacturer. Says the expanded agreement will see it supply a thermal interlayer which will replace its current phase change material technology. Adds that it will also supply motorbike PPE to enhance the safety and comfort of motorbike riders. Chief Executive Giulio Cesareo says: ‘We are thrilled to strengthen our partnership with Miguel Caballero, a leader in the protective wear industry, and to be part of their journey towards creating safer, more advanced protective solutions for individuals in high-risk professions. This collaboration expansion reflects our commitment to driving innovation and sustainability in the textile industry and we look forward to working closely with CIA Miguel Caballero to provide even more innovative solutions to their customers.’
----------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
